Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.

[1]  W. Colucci.  III. Antagonist's viewpoint , 1988 .

[2]  Milton Packer.  II. Protagonist's viewpoint , 1988 .

[3]  R. Cody.  Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction. , 1988, Journal of the American College of Cardiology.

[4]  N. Sharpe,et al.  TREATMENT OF PATIENTS WITH SYMPTOMLESS LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 1988, The Lancet.

[5]  D. Taylor,et al.  Double-blind crossover comparison of enoximone and placebo in patients with congestive heart failure. , 1987, Circulation.

[6]  C. Sweet,et al.  Increased Survival in Rats with Congestive Heart Failure Treated with Enalapril , 1987, Journal of cardiovascular pharmacology.

[7]  H. R. Kaplan,et al.  Subclasses of Cyclic AMP‐Specific Phosphodiesterase in Left Ventricular Muscle and Their Involvement in Regulating Myocardial Contractility , 1987, Circulation research.

[8]  F. Butzer,et al.  A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure. , 1987, The American journal of cardiology.

[9]  Bigger Jt.  Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. , 1987 .

[10]  M. Packer,et al.  Survival in congestive heart failure during treatment with drugs with positive inotropic actions. , 1987, Circulation.

[11]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[12]  F. Schoen,et al.  Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. , 1987, Circulation.

[13]  H. Schieffer,et al.  Withdrawal of long-term amrinone therapy in patients with congestive heart failure: a placebo controlled trial. , 1986, European heart journal.

[14]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[15]  Katz Am.  Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. , 1986 .

[16]  J. Anderson,et al.  Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone. , 1986, American heart journal.

[17]  D. Baim,et al.  Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal. , 1986, Circulation.

[18]  J. S. Janicki,et al.  Milrinone in the treatment of chronic cardiac failure: a controlled trial. , 1985, American heart journal.

[19]  P. Kligfield,et al.  Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias. , 1985, American heart journal.

[20]  R. Cody,et al.  Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. , 1985, Journal of the American College of Cardiology.

[21]  M. Pfeffer,et al.  Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. , 1985, Circulation.

[22]  M. Pfeffer,et al.  Influence of Chronic Captopril Therapy on the Infarcted Left Ventricle of the Rat , 1985, Circulation research.

[23]  B. Massie,et al.  Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. , 1985, Circulation.

[24]  M. Packer,et al.  Does inotropic therapy shorten survival in patients with severe chronic heart failure , 1985 .

[25]  M. Packer,et al.  Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. , 1984, Circulation.

[26]  M. Packer,et al.  Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. , 1984, American Journal of Cardiology.

[27]  C. Leier,et al.  Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. , 1984, Journal of the American College of Cardiology.

[28]  M. Davies,et al.  Inotropic and vasodilator effects of amrinone on isolated human tissue. , 1984, Cardiovascular research.

[29]  E. Sonnenblick,et al.  Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. , 1983, Journal of the American College of Cardiology.

[30]  E. Sonnenblick,et al.  Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease. , 1982, The American journal of medicine.

[31]  Lee Jc,et al.  Cyclic AMP and the pathogenesis of myocardial injury. , 1980 .

[32]  E. Braunwald,et al.  Hemodynamic assessment of amrinone. A new inotropic agent. , 1978, The New England journal of medicine.

[33]  L. Opie,et al.  CYCLIC ADENOSINE MONOPHOSPHATE, VENTRICULAR FIBRILLATION, AND ANTIARRHYTHMIC DRUGS , 1976, The Lancet.

[34]  Miles Be,et al.  Letter: Serum-phenytoin. , 1976 .

[35]  A. Govaerts,et al.  CANCER, ASTHMA, AND CYCLIC A.M.P. , 1975, The Lancet.

[36]  P. Martorana.  The role of cyclic AMP in isoprenaline‐induced cardiac necroses in the rat * , 1971, The Journal of pharmacy and pharmacology.